PharmaCorp Rx Inc. PCRX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 143.05% | -53.20% | -220.58% | 56.53% | 36.24% |
| Total Depreciation and Amortization | 76.89% | 96.71% | 79.24% | 190.29% | 731.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -293.28% | 914.55% | 143.05% | -73.53% | -893.33% |
| Change in Net Operating Assets | 1,387.78% | -1,043.85% | 141.07% | 215.90% | -92.66% |
| Cash from Operations | 516.93% | -2,255.15% | 36.35% | 184.75% | -24.26% |
| Capital Expenditure | -142.23% | -233.16% | -- | -- | -312.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 67.10% | -- | 105.06% | -387.04% | -1,356.83% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.85% | -- | -- | -- | -- |
| Cash from Investing | 87.67% | -301.60% | 83.91% | -288.33% | -4,330.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 27.34% | -110.06% | -214.68% | -49.88% | -158.17% |
| Issuance of Common Stock | -- | -- | -- | -58.58% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 596.15% | 653.54% | 42,799.18% | -59.80% | -100.20% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 118.78% | -5,143.92% | 251.89% | -192.33% | -116.89% |